Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-9591 in EGFR-Mutated NSCLC with Brain or Leptomeningeal Metastases
NCT05146219Phase 2Completed
- Sponsor
- TYK Medicines
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Primary endpoints: Intracranial Overall Response Rate at 13 months and Extracranial Overall Response Rate at 13 months. Started Apr 2022; status: completed.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05146219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146219.